Companies Dominating the Biologics CDMO Landscape
- 3P Biopharmaceuticals
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AbbVie Inc.
- AGC Biologics
- Binex Co. Ltd.
- Boehringer Ingelheim International GmbH
- Bora Pharmaceuticals
- Kemwell Biopharma Pvt. Ltd.
- Lonza Group Ltd.
- Novartis AG
- Eurofins Scientific
- Rentschler Biopharma SE
Key companies in the biologics CDMO market are innovating by investing in advanced technologies such as cell and gene therapies, AI-driven process optimization, and state-of-the-art processing capabilities. They focus on enhancing bio-engineered assembly through scalable, efficient, and cost-effective solutions. Additionally, they are forming strategic partnerships to strengthen their service offerings and expand their geographic presence. For instance, in February 2024, Eurofins CDMO Alphora Inc. empowered its market grip by combining expertise in API/HPAPI with advanced biologics capacity and enhancing development capabilities through its new pilot-scale facility. Such innovations accelerate drug development and increase capacity. Some of these key companies are:
